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bstract
5-S-cysteinyldopa is a well-known pigment intermediate and analysis of its plasma concentration is interesting for the early diagnosis, as well
s for evaluation of treatment and follow-up of malignant melanoma. A determination method of 5-SCD in human plasma was developed using
olid phase extraction (SPE) on disposable cartridges and liquid chromatography electrospray mass spectrometry (LC-ESI–MS–MS). Compound’s
ensitivity to light and oxidation requires the addition of anti-oxidative agents (AO), to work in acidic media at 4 ◦C and to avoid light exposure
f samples since blood collection. Different solid phases involving covalent binding to phenylboronic groups or dual retention mechanisms were
valuated and extraction cartridges containing both hydrophobic and strong cation exchange functionalities were finally selected. The LC separation
f 5-SCD from endogenous catecholamines was achieved by gradient elution on a C18 stationary phase. 5-SCD was detected by multiple reaction
onitoring (MRM) performed on ES(+) generated ions. Finally, the method was prevalidated in the lower ng/ml range. Good results with respect
o accuracy, trueness and precision were obtained.
2006 Elsevier B.V. All rights reserved.







Incidence of malignant melanoma is in constant progres-
ion in caucasian population. This disease is characterised by a
reat metastatic potential and therefore by a very unfavourable
rognosis. Malignant melanoma is a tumour which develops
t the expense of the melanocytical cell system. It affects pre-
ominantly the skin and more rarely the nails or the mucous
embranes. Considering that no therapy has shown its efficiency
n the survival of patients in the metastatic phase, the early detec-
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oi:10.1016/j.chroma.2006.12.088ion of melanomas seems to be of the utmost importance as well
s the development of preventive measures particularly in terms
f photoprotection [1–4].
Among the known plasmatic biomarkers of melanoma, 5-
-l-cysteinyl-l-dopa (5-SCD) seems to constitute an excellent
etector of metastasis and parameter of disease progression,
howing significant elevation with the occurrence of metasta-
is and with the progression of the disease earlier than physical,
adiological or other laboratory investigations [5–9].Oxidation of cysteinyldopa isomers in melanocytes leads to
he production of pheomelanin, a yellow to reddish melanin, but
significant portion of cysteinyldopa escapes from melanocytes,




































































242 G.B. Martin et al. / J. Chro
rogression of melanoma by measuring the concentration of
-SCD in blood or urine [1,6–21].
Since then, levels of 5-SCD were always measured by
igh-performance liquid chromatography with electrochemical
etection [7,21–23]. Concerning the extraction of 5-SCD from
iological matrix, alumina extraction [9–13] was very often
pplied prior to HPLC analysis, sometimes coupled with an addi-
ional liquid–liquid extraction step. Enrichment methods with
henylboronate affinity gel have also been described [14,15].
inally, phenylboronic acid SPE cartridges were successfully
sed by Hartleb and Huang [16,17].
For the first time we have developed a HPLC–mass spectrom-
try (MS) method for the determination of 5-SCD in plasma.
igh sensitivity and specificity were obtained using multiple
eaction monitoring (MRM) performed on ES(+) generated ions.
everal types of automated solid phase extraction procedures
ere tested in order to extract 5-SCD from plasma in a MS
ompatible manner. The sensitivity of the compound of interest
o oxidation and light exposure has been taken into account. The
ntire method was then prevalidated at the nanogram level.
. Materials and methods
.1. Chemicals and reagents
5-SCD was prepared as previously described [24,25]. -
ethyldopa was supplied by Acros organics (NJ, USA). Their
hemical structures are presented in Fig. 1. Epinephrine was
btained from Bufa (Netherland) and norepinephrine from
igma–Aldrich (St. Louis, MO, USA). Dopamine, levodopa,
ormic acid (98–100%) and ammonia solution (28–30%) were
rom Acros organics (NJ, USA). Hydrochloric acid (37%),
ethanol HPLC grade and acetic acid (100%) were sup-
lied by Merck (Darmstadt, Germany). Water and methanol
f LC–MS grade were obtained from Biosolve (Netherland).
scorbic acid was from Certa (Braine-l’Alleud, Belgium) and o-
hosphoric acid (minimum 85%) from UCB (Leuven, Belgium).
ll reagents were of analytical grade. Water used in most exper-ments was of Milli-Q quality (Millipore, Bedford, MA, USA).
asis MCX sorbent (30 mg/ml) were obtained from Waters
Milford, MA, USA). Other sorbents, namely Oasis MAX
30 mg/ml) from Waters, Bond Elut PBA (100 mg/ml) from Var-
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an (Harbor City, CA, USA) and Isolute HCX-3 (130 mg/ml)
rom International Sorbent Technology (Mid Glamorgan, UK),
ere also tested. Nitrogen (alphagaz 1) and argon (alphagaz 2)
ere purchased from Air Liquide (Milmort, Belgium).
.2. Apparatus
Experiments were carried out with a HPLC equipped with
binary pump, an autosampler, a thermostated column com-
artment and a diode-array detector, all HP series 1100 from
ewlett-Packard (Waldbronn, Germany). The LC model cou-
led to the MS system possessed a quaternary pump, a vacuum
egasser, an autosampler and a thermostated column com-
artment (HP 1100 series, Agilent Technologies, Waldbronn,
ermany). A LC Chemstation (Hewlett-Packard) was used for
nstrument control, data acquisition and data handling, when UV
etection was performed. MS detection was carried out using
n Ultima triple quadrupole instrument (Micromass, Manch-
ster, UK) operating under MassLynx 3.5 and configured with
Z-spray electrospray ionization source. The separation was
erformed on an Atlantis dC18 column (100 mm × 2.1 mm,
.d.; particle size: 3m) from Waters. An Alltima HP C18
mide (250 mm × 3.0 mm, i.d.; particle size: 5m) from All-
ech Associates Inc. (Deerfield, IL, USA) was also tested. The
SPEC system (automated sample preparation with extraction
artridges) from Gilson (Villers-le-Bel, France) consisted of a
ample processor equipped with an xyz-motion robotic arm,
401C dilutor/pipettor connected to a needle attached to the
obotic arm and a set of rack and accessories for handling dispos-
ble extraction cartridges, samples and solvents. A 722 keypad
oftware from Gilson was used for the control of the ASPEC
ystem.
The e.noval® software (Arlenda, Belgium) was used to obtain
he accuracy profiles as well as all prevalidation results.
.3. Chromatographic conditions
The chromatographic separation of 5-SCD from endogenous
atecholamines was achieved by gradient elution on a C18 sta-
ionary phase compatible with mobile phases with very low
ontent of organic modifier. The mobile phase consisted for one
art of 0.1% (v/v) formic acid in water and for the other part
f 0.1% (v/v) formic acid in methanol. The content of organic
odifier increased from 0 to 10% in 10 min. Prior to use, mobile
hases were degassed for 15 min in an ultrasonic bath. The chro-
atographic separation was performed at 20 ◦C using a constant
ow rate of 0.25 ml/min. The injected volume was 20l and the
hermostated autosampler was set to 10 ◦C.
.4. Extraction technique
.4.1. Final conditions on Oasis MCX cartridges
The automatic procedure was started by the washing of theeedle of the dilutor with a mixture of methanol and water
10:90, v/v). Between each step of the sample handling, the
eedle was rinsed with the same volume of this methanol–water
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ubing before aspiration of other liquids in order to avoid
ross-contamination. The following optimized SPE procedure
as then applied for Oasis MCX cartridges: (i) conditioning
f the extraction support (flow rate: 1.5 ml/min; air volume:
ml): the sorbent was treated first by 1.0 ml of methanol and
hen by 1.0 ml of 0.1 M hydrochloric acid. (ii) Loading of the
lasma sample (flow rate: 0.18 ml/min; air volume: 1 ml): a 2 ml
olume of acidified plasma sample was applied on the sorbent
t the minimum dispensing flow rate in order to maximize
he analyte retention. (iii) Washing (flow rate: 1.5 ml/min;
ir volume: 1 ml): the sorbent was successively washed with
.0 ml of 0.1 M hydrochloric acid and 1.0 ml of methanol. (iv)
lution (flow rate: 1.5 ml/min; air volume: 1 ml): 5-SCD and
-methyldopa were eluted from the sorbent with 0.5 ml of the
ixture methanol/water/ammonia (80:10:10, v/v/v) containing
.1% ascorbic acid. This step was followed by the automated
cidification of the eluate with 100l of formic acid in order to
inimize the degradation of the catecholamines by oxidation.
he eluate was collected and gently evaporated to dryness under
nitrogen stream. The dried extracts were finally reconstituted
n 500l of water containing 0.1% formic acid and 0.1%
scorbic acid, the solution was submitted to centrifugation and
he supernatant was injected into the LC system.
.4.2. Initial conditions for Bond Elut PBA cartridges
Conditioning of the sorbent was performed in applying
ethanol followed by Tris buffer (1.0 ml each); then, the sam-
le constituted by 5-SCD and -methyldopa (10g/ml each) in
ris buffer was loaded on the support; Tris buffer followed by
mixture of methanol/Tris buffer 5:95 (v/v) (1.0 ml each) was
sed for the washing step and finally, elution of the analytes was
ossible with 0.3 ml of a mixture of 3 M formic acid + 4 mM
SH (pH 1.5)/acetonitrile 95:5 (v/v).
.4.3. Initial conditions for Oasis MAX cartridges
The stationary phase was conditioned by 1.0 ml methanol
ollowed by 1.0 ml of 50 mM acetate buffer (pH 9); loaded with
solution of 5-SCD and -methyldopa (10g/ml) in 50 mM
cetate buffer (pH 9) and washed by 1.0 ml of the same buffer.
he compounds of interest were eluted by 0.5 ml of a solution
f methanol containing 2% acetic acid.
.4.4. Initial conditions for Isolute HCX-3 and Oasis MCX
artridges
Methanol followed by a 50 mM formate buffer (pH 2.5) was
sed for support conditioning. The sample loaded was composed
f a formate buffer (pH 2.5) containing the 5-SCD and its internal
tandard at a concentration of 10g/ml each. The washing of
he sorbent was performed with 1.0 ml of the 50 mM formate
uffer (pH 2.5) and, finally, the analytes were eluted by 0.5 ml
f a solution of methanol containing 2% of ammonia.
.5. Mass spectrometry detectionMass spectrometric detection was carried out using an Ultima
riple quadrupole (Micromass) apparatus equipped with an elec-
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ts internal standard were detected by multiple reaction monitor-
ng (MRM) performed on electrospray positive generated ions.
he source was heated up to 120 ◦C and the desolvation temper-
ture was fixed at 450 ◦C. The applied voltages for the capillary
nd the cone were, respectively, 3.0 kV and 30 V and the gas
ow rates were set at 160 l/h for the cone and 750 l/h for the
esolvation. The mass spectrometer generated and selected the
seudomolecular ions [MH+] at m/z 317 for 5-SCD and 212 for
-methyldopa by the intermediate of the first quadrupole mass
lter (Q1). The fragmentation was then performed in the colli-
ion cell (Q2) by applying a collision energy of 25 eV. Signals
ere monitored from the third quadrupole (Q3) at m/z 155 and
66 for 5-SCD and internal standard, respectively.
.6. Standard solutions
.6.1. Solutions used for method development with UV
etection
A solution of epinephrine, norepinephrine, dopamine, lev-
dopa, 5-SCD and -methyldopa was prepared by dissolving
he appropriate amounts of analytes in 10 mM hydrochloric acid
olution in order to obtain a concentration of 0.4 mg/ml for each
atecholamine. From this solution, diluted solutions were pre-
ared in the same media to reach final concentrations of 40 and
00g/ml. Samples which were submitted to the extraction pro-
edure (water or plasma acidified by 2% phosphoric acid) were
piked with 25l of these three solutions.
.6.2. Solutions used for method development with MS
etection
Two stock solutions of 5-SCD and -methyldopa were pre-
ared by dissolving the appropriate amounts of analytes in
0 mM hydrochloric acid solution in order to obtain a con-
entration of 0.3 mg/ml. These stock solutions were diluted in
he same media to reach concentrations ranging from 60 to
000 ng/ml. 25l of these diluted solutions was spiked in the
cidified plasma samples before the extraction procedure.
Ascorbic acid stock solution was prepared by dissolving
00 mg of the anti-oxidative compound in 10 ml of 10 mM
ydrochloric acid solution.
.6.3. Solutions used for prevalidation phase
An appropriate amount of 5-SCD was dissolved in 10 mM
ydrochloric acid solution in order to obtain a concentration of
2g/ml (stock solution). Dilutions of the stock solution were
erformed to reach final concentrations of 64, 192, 384, 4000
nd 8000 ng/ml. In the same way, stock and diluted solutions of
-methyldopa were prepared in order to obtain a final concentra-
ion of 2000 ng/ml. All diluted solutions were freshly prepared.
Daily, plasma stored at −80 ◦C was first thawed at ambi-
nt temperature in the darkness and centrifuged at 4500 rpm for
0 min. A mixture containing 25l of the ascorbic acid stock
olution, 25l of the 5-SCD solution and 25l of the internal
tandard solution was prepared. Plasma previously acidified by
% phosphoric acid was then added up to 1 ml and the final sam-
le was mixed. The spiked plasma samples were then introduced
nto tubes of the ASPEC sample processor. Two calibration



















































Fig. 2. Chromatogram illustrating the separation of cysteinyldopa from endoge-
nous catecholamines, levodopa (anti-parkinsonian agent) and -methyldopa
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urves ranging from 1.6 to 200 ng/ml (k= 2) were performed
n the matrix, every one by using new diluted solutions and each
alibration standard was injected in duplicate (n= 2). In addi-
ion, daily, a calibration curve without the matrix was directly
njected into the LC–MS–MS system.
. Results and discussion
.1. Optimization of mass spectrometric and
hromatographic conditions
MS detection parameters were optimized by direct injection
f reference compounds in solution using the electrospray inter-
ace in the positive mode of ionisation. Values for cone and
apillary voltages, cone and desolvation gas flows and tem-
eratures were determined in order to obtain the best signal
or 5-SCD in particular (cf. Section 2). The highest protonated
olecular ions generated under a stable spray, corresponding to
he [M + H]+ ionic species, were detected at m/z ratio of 317 for
-SCD and 212 for the internal standard.
The collision energy was optimized in order to reach a max-
mum intensity for the fragment ion resulting in a minimum
esponse for the molecular ionic species. As for the other param-
ters, the determination of collision energy was focused on
-SCD since this analyte has shown a poorer sensitivity than the
nternal standard. Different intensities of energy were applied in
he collision cell producing, for cysdopa: three significant frag-
ent ions of m/z 271, 228 and 155. Fragment ion at m/z 271 was
nly present at low collision energy (<10 eV) while ion at m/z
28 was detected until an energy of 20 eV. The MS/MS transi-
ion 317/155 was therefore selected since the ion scan product
ith m/z 155 presented systematically the higher abundance.
n order to be more selective, the intensity of collision energy
as fixed to 25 eV. Literature confirms this choice since this
on was described as belonging to the relationship of cysdopa
ragment ions obtained after electronic impact and fast atoms
ombardment [26]. It was identified as a dihydroxymercap-
obenzyle cation. For -methyldopa, a 25 eV collision energy
roduced significant fragment ions with m/z ranging from 93
o 166. The fragment ion with the highest m/z ratio (m/z 166)
resented a high intensity and could be selected for quantitative
S detection in the multiple reaction monitoring (MRM) mode
n order to avoid interferences.
As MRM is based on the transition involving the specific
olecular ion and a characteristic fragment ion, high detec-
ion selectivity as well as high signal-to-noise ratios could
e obtained providing a clean RP–LC–MS–MS/MRM chro-
atogram. This detection mode is far more specific than the
lectrochemical detection which has been used since then to
etermine 5-SCD. It is also sensitive since a level of 1.6 ng/ml
f 5-SCD in plasma was detectable. Reference values generally
dmitted are 1.6 and 3.2 ng of 5-SCD by milliliter of plasma,
orresponding, respectively, to the maximum of normal values
nd to the pathological threshold.
In order to obtain an optimal sensitivity, a complete separation
f 5-SCD, its internal standard and other catecholamines was




w.1% formic acid in water and (B) 0.1% formic acid in methanol. Sample:
atecholamines (10g/ml) in (A). Peaks (1) norepinephrine; (2) epinephrine;
3) dopamine; (4) levodopa; (5) 5-SCD; (6) -methyldopa.
The relatively high polarity of the catecholamines requested
he use of mobile phases containing a very low content of organic
odifier. The chromatographic separation was first performed
n an amidooctadecyl silica stationary phase (HP C18 amide)
ith a mobile phase containing 1% of acetonitrile. But when
his method was transferred to mass spectrometry, the mobile
hase volatilization was found to be difficult. An octadecyl
ilica stationary phase particularly adapted to aqueous mobile
hases (Atlantis dC18) was then tested. The first experimen-
al conditions involved the use of a mobile phase composed
f a mixture of 100 mM ammonium formate/water/acetonitrile
10:85:5, v/v/v) in the isocratic mode but no catecholamine was
eparated from each other. Resolution was only obtained after
emoving the organic modifier. However, in order to obtain a
ufficient volatilization of the mobile phase after transfer of the
ethod to mass spectrometry, a minimum content in organic
odifier was needed. Complete separation of cysdopa and its
nternal standard was finally achieved by gradient elution. The
queous fraction of the mobile phase was composed of water
ontaining 0.1% of formic acid while the organic part was a
olution of methanol containing 0.1% of formic acid. The con-
ent in organic modifier increased from 0 to 10% in 10 min. As
an be seen in Fig. 2, the retention times were approximately
and 7 min for 5-SCD and -methyldopa, respectively, mak-
ng the content in methanol sufficient to ensure a satisfactory
olatilization of the mobile phase.
.2. Optimization of the solid phase extraction procedure
Prior to LC analysis, an automated solid phase extraction
rocedure was selected for plasma sample clean-up in order to
liminate endogenous compounds that might interfere with the
uantification. Moreover, an increase of the analyte concentra-
ions could be obtained after application of this technique.
Structurally similar to catecholamines, 5-SCD presents a
atechol ring, a phenyl substituted by two hydroxyl groups
n positions 3 and 4, carrying an ethylamine chain on the
rst carbon atom. Considering this property, the choice of the
xtraction sorbent was aimed towards a silica phase bonded
ith phenylboronic groups which form covalent bindings with
G.B. Martin et al. / J. Chromatog
Table 1
Influence of the presence of TBA in the conditioning buffer and in the sample
solution on the recoveries
Recoveries (%) ± SD (n= 2)
Cysdopa Methyldopa

















































































2, 5 and 10% of ammonia. Since no significant difference was
observed, a content of 10% in ammonia was selected in order
to ensure the strongest elution of the analytes. Fig. 3 also illus-
trates the analyte recovery obtained after addition of water in theC + TBA 5 mM 83.7 ± 6.8 90.9 ± 3.5
ata obtained on Bond Elut PBA cartridges; initial conditions as given in Section
; UV detection at 293 nm.
icinal diols leading to ester formation. Because of the high
ensibility of 5-SCD to oxidation, the experiments had to be
erformed under shelter from light, at a temperature of 4 ◦C
nd with addition of anti-oxidative substances: 4 mM reduced
lutathione (GSH) and 5 mM ethylenediaminetetraacetic
iammonium salt ((NH4)2EDTA). The buffer used in the differ-
nt steps of the extraction process was constituted of 100 mM
ris(hydroxymethyl)aminoethane (Tris buffer) containing these
wo anti-oxidative substances. The elution solution was com-
osed of a mixture of 3 M formic acid containing 4 mM GSH
djusted to pH 1.5 with ammonia and acetonitrile in a 95:5 (v/v)
atio. Low recoveries were obtained for levodopa, 5-SCD and
-methyldopa due to losses during the washing step (Table 1).
his phenomenon has been already observed by Hartleb et
l. [16]. Higher recoveries for these compounds in aqueous
olution were only obtained by addition of tetrabutylammo-
ium chlorure salt (TBA) to all the extraction process steps
Table 1). The content in TBA was further optimized in order
o improve the recoveries. Addition of 2 mM of TBA gave rise
o excellent recoveries of analytes in plasma samples with UV
etection (91.4 ± 0.6 and 88.5 ± 0.3 (mean (%) ± SD; n= 2)
or 5-SCD and -methyldopa, respectively). Unfortunately,
hose conditions could not lead to reproducible responses when
ransferred in mass spectrometry, due to ion suppression effects
probably coming from TBA, GSH and EDTA).
Other types of sorbents, involving the use of more compatible
omponents to MS demands, were then tested. Three kinds of
orbent providing a dual retention mechanism with both nonpo-
ar and strong ion exchange functionalities (Oasis MAX, Isolute
CX-3, Oasis MCX) were evaluated (Table 2). The extraction
upport differed on the one hand by the nature of the ionized
ompounds involved in the exchange mechanism, anions for
AX and cations for HCX and MCX. Both exchangers could
e employed since the analytes contain amino and carboxylic
roups (Fig. 1). On the other hand, the nature of the sorbent
able 2
nfluence of the type of mixed-mode extraction sorbents on the recoveries (%)
f cysdopa and the internal standard in aqueous solution





nitial conditions for Oasis MAX or Isolute HCX-3 and Oasis MCX as given in




Or. A 1156 (2007) 141–148 145
as also different, silica for HCX and polymer composed of
ydrophilic N-vinylpyrrolidone and lipophilic divinylbenzene
or MAX and MCX. In addition to the resistance to extreme pH,
balanced ratio of these two monomers provides an excellent
etention for polar compounds and a three-fold higher relative
etention capacity when compared with traditional silica-based
orbent like C18. The pKa values, corresponding to a carboxylic
roup, and an amino group, were 2 and 9.4 for 5-SCD, respec-
ively, and 2.2 and 10.6 for-methyldopa. In order to obtain good
etention and elution conditions, a pH value of 2.5 was chosen in
rst intention for conditioning, loading and washing the HCX or
CX supports while the elution was performed with methanol
ontaining 2% of ammonia. The anionic exchanger was tested
ith pH 9 buffer for the whole procedure but the elution was
erformed with methanol containing 2% of acetic acid.
As can be seen in Table 2, the application of aqueous sam-
les on the MAX support gave rise to low recoveries. This can
e partially explained by losses of analytes observed during the
xtraction process (during the loading and the washing steps).
n the other hand, no loss of 5-SCD and/or -methyldopa (dur-
ng the loading and the washing steps) was observed when the
orbent was a polymeric phase instead of bonded silica. MCX
artridges were therefore selected as extraction support and more
rastic pH conditions (0.1 M HCl) were applied for the condi-
ioning and the washing steps.
Nevertheless, recoveries remained relatively low due to
ncomplete elution of analytes. For that reason, the optimal com-
osition of the elution solution was investigated. Among the
ifferent organic solvents evaluated for the elution step (acetoni-
rile, methanol, isopropanol and ethyl acetate), methanol gave
ise to better results (data not shown). To further improve the ana-
yte recovery, ammonia was chosen as counter-ion because of
ts perfect volatility and, therefore, its compatibility with mass
pectrometry. The influence of the content of ammonia in the
lution solution on the recoveries of 5-SCD was investigated in
queous solution (Fig. 3) and the best results were obtained forig. 3. Influence of the composition of the elution solution on the recovery of
ysdopa (%): (i) content of ammonia in methanol (ammonia) and (ii) content of
ater in a mixture of methanol and 10% of ammonia (water); extraction support:
asis MCX. Other conditions as given in Section 2.

































big. 4. Accuracy profile obtained by considering: (A) linear regression, (B) quad
egression; plain line: relative bias, dashed lines: -expectation tolerance lim
oncentrations.
lution solution. 5 and 10% of water led to a three-fold increase
f the analyte recovery. More reproducible results with 10% of
ater were obtained for the handling of plasma samples (data
ot shown). Due to the instability of catecholamines and partic-
larly 5-SCD in basic conditions, an anti-oxidative substance,
scorbic acid, at a concentration of 0.1% was finally introduced
n the eluting mixture before the eluting step giving rise to bet-
er recoveries, 88.9 ± 1.1 and 93.3 ± 1.5 (mean (%) ± SD; n= 2)
or 5-SCD and -methyldopa, respectively, in aqueous solution
nd by applying UV detection. Finally, the application of the
hole SPE–LC–MS–MS method to spiked plasma samples led
o excellent recoveries for cysdopa: 80.4 ± 3.0 (mean (%) ± SD;
= 20).
.3. Stability
The sensitivity of 5-SCD against oxidation and light was
aken into consideration from the beginning of the procedure.
ndeed, for the standard solution, we always worked with
0 mM hydrochloric acid solution in which 5-SCD and the cat-




fregression, (C) weighted 1/x2 linear regression and (D) weighted 1/x2 quadratic
tted curves: acceptance limit (20%) and green dots: relative back-calculated
80 ◦C (data not shown). The spiked plasma samples were pre-
iously acidified by 2% phosphoric acid, which guarantees the
tability of the compound of interest.
5-SCD was in the presence of alkaline solution only during a
ery short period of time (less than 1 min) corresponding to the
lution step on the MCX cartridges, but oxidation phenomenon
ould be avoided thanks to the addition of ascorbic acid in the
lution solution and immediate acidification of the eluate with
ormic acid (cf. Section 2).
During all the SPE and the LC–MS–MS procedures, the
amples were stored at 4 ◦C and in the darkness.
.4. Method prevalidation
An original approach using accuracy profiles based on toler-
nce intervals for the total measurement error, including both
ias and standard deviation for intermediate precision, was
pplied to demonstrate the method capability to quantify [27,28].
or this approach two parameters must be set, the acceptance
imits on one hand and the risk of having future measurements
alling outside those acceptance limits on the other hand. The
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Table 3
Prevalidation results
Response function (k= 2) Weighted quadratic regression model (calibration range (m= 5): 1.6–200 ng/ml)
Series 1 Series 2




































































: Number of days of experiments (series); m: number of concentration levels; n
cceptance limits were set at ±20% as proposed by the FDA
ocument [29]. In the same document, for the in-study valida-
ion, a run is accepted by applying the 4–6–20 rule, i.e. at least 4
esults out of 6 must be within the acceptance limits of ±20%.
n other words this means that the risk of having results falling
utside the acceptance limits accepted during routine analysis is
qual to 33.33%. In order to make the prevalidation in agreement
ith this routine analysis acceptance rule, the risk was therefore
et at 33.33% in the present study.
To prevalidate the analytical procedure, the standard addition
ethod had to be used. Indeed the analyte studied is naturally
resent in the matrix. Therefore, calibration curves were made
y spiking plasma in order to reach 5 concentration levels rang-
ng form 1.6 to 200 ng/ml of added 5-SCD. For each calibration
urve four calibration standards were analyzed at each concen-
ration level for 2 days. Quadratic and linear regression models
ere fitted as well as the weighted by 1/x2 quadratic and lin-
ar models to look for the most adequate response function.
o achieve this, the concentrations of the calibration standards
ere back-calculated using each regression model in order to
etermine, by concentration level, the mean relative bias, the
tandard deviation intermediate precision as well as the upper
nd lower -expectation tolerance limits [27,28,31] and there-




cber of replicates per concentration level and per series.
uitable regression model for the intended use of the analyti-
al method was selected on the basis of these profiles as shown
n Fig. 4. When the acceptance limits were set at ±20% accord-
ng to the regulatory requirements [29], only the two weighted
egression model allowed demonstrating the capability of the
ethod to quantify 5-SCD over the concentration range consid-
red, since the tolerance intervals were totally included inside
he acceptance limits. However the model selected was the
eighted 1/x2 quadratic regression as it is the one showing
he best overall trueness and precision. The response func-
ion obtained by applying this regression model is presented in
able 3.
From these results, the concentration of the endogenous
-SCD was estimated via the responses functions used each
ay. The estimated concentration of the native 5-SCD was
f 2.18 ng/ml. In order to confirm this, four samples of
ative plasma were analyzed each day and their concentration
ack-calculated with their respective calibration curve. If this
ssumption was acceptable then the back-calculated concen-
ration should be close to 0 ng/ml. This was verified by usingStudent’s t-test. Indeed, the back-calculated concentrations
ere considered not to be different from 0 ng/ml as the con-
dence interval of the mean result included the value 0 (95%


































































135.48 G.B. Martin et al. / J. Chro
Trueness [27,28,32] expressed in terms of relative bias (%)
as then assessed from the calibration standards for 5-SCD at
concentration levels as can be seen in Table 3. According to
he regulatory requirements [29], trueness was acceptable since
he bias did not exceed the value of ±15%, irrespective of the
oncentration level.
The precision of the bioanalytical method was determined
y computing the relative standard deviations (RSD) for
epeatability and time-different intermediate precision at each
oncentration level of the calibration standards [27–29]. The
SD values presented in Table 3 were also acceptable as they
id not exceed ±15%. These results illustrate the good precision
f the developed method.
Accuracy takes into account the total error, i.e. the sum
f systematic and random errors, related to the test result
27–29,31,32]. As shown in Table 3, the upper and lower -
xpectation tolerance limits (%) did not exceed the acceptance
imits settled at ±20% for each concentration level. Conse-
uently, the method can be considered as accurate over the
oncentration range investigated [27–29]. Therefore, the lower
imit of quantitation (LOQ) was 1.6 ng/ml. The limit of detection
LOD) was estimated using the mean intercept of the calibration
odel and the residual variance of the regression. The LOD was
valuated at 0.18 ng/ml.
. Conclusions
5-SCD in plasma was determined for the first time by
sensitive and selective LC-ESI–MS–MS method. A new
xtraction method using sorbent filled with a solid phase con-
aining hydrophobic and cation exchange functional groups
as finally chosen and optimized. The extreme sensitivity of
-SCD against oxidation and light was taken into consider-
tion from the beginning of the procedure. Good recoveries
ere obtained for 5-SCD in plasma samples and accuracy
f the method was demonstrated. Because the accuracy pro-
le was within the acceptance limits set at 20% according to
he FDA regulations (Bioanalytical Method Validation: CDER:
ttp://www.fda.gov/cder/guidance) in the concentration range of
.6–200 ng/ml, it was demonstrated that the analytical method
ulfils its objective, that is the accurate quantification of 5-SCD
n plasma.
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